Tocilizumab in patients with multisystem Erdheim–Chester disease

Treatment of Erdheim–Chester disease (ECD), a rare non-Langerhans histiocytosis, relies on interferon-α, chemotherapeutic agents such as purine analogs, cytokine-blocking agents and BRAF inhibitors. Since interleukin (IL)-6 levels are elevated in serum and lesions of ECD patients, we evaluated the t...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncoimmunology
Glavni autori: Berti, Alvise, Cavalli, Giulio, Guglielmi, Barbara, Biavasco, Riccardo, Campochiaro, Corrado, Tomelleri, Alessandro, Nicoletti, Roberto, Panzacchi, Andrea, Ferrarini, Marina, Dagna, Lorenzo
Format: Artigo
Jezik:Inglês
Izdano: Taylor & Francis 2017
Teme:
Brief Report
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5486186/
https://ncbi.nlm.nih.gov/pubmed/28680751
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2017.1318237
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items